Univest Sec Begins Coverage on Yield10 Bioscience (NASDAQ:YTEN)

Research analysts at Univest Sec assumed coverage on shares of Yield10 Bioscience (NASDAQ:YTEN – Get Rating) in a research note issued to investors on Tuesday, The Fly reports. The firm set a “buy” rating on the specialty chemicals company’s stock.

A number of other equities analysts have also weighed in on the stock. Zacks Investment Research upgraded shares of Yield10 Bioscience from a “sell” rating to a “hold” rating in a report on Tuesday, April 12th. Lake Street Capital started coverage on shares of Yield10 Bioscience in a report on Thursday, April 21st. They issued a “buy” rating and a $12.00 price objective for the company. Finally, Maxim Group decreased their price objective on shares of Yield10 Bioscience from $18.00 to $9.00 and set a “buy” rating for the company in a report on Thursday, March 10th.

Shares of YTEN opened at $2.90 on Tuesday. The business’s 50 day moving average price is $4.30 and its 200-day moving average price is $4.64. Yield10 Bioscience has a 52 week low of $2.75 and a 52 week high of $10.87. The stock has a market cap of $14.18 million, a P/E ratio of -1.24 and a beta of 1.54.

Yield10 Bioscience (NASDAQ:YTEN – Get Rating) last announced its quarterly earnings data on Wednesday, March 9th. The specialty chemicals company reported ($0.61) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.03. Yield10 Bioscience had a negative net margin of 1,796.58% and a negative return on equity of 56.52%. The company had revenue of $0.15 million during the quarter, compared to analyst estimates of $0.10 million. During the same period in the previous year, the business earned ($0.79) EPS. As a group, sell-side analysts forecast that Yield10 Bioscience will post -2.87 EPS for the current fiscal year.

An institutional investor recently raised its position in Yield10 Bioscience stock. Geode Capital Management LLC raised its stake in shares of Yield10 Bioscience, Inc. (NASDAQ:YTEN – Get Rating) by 10.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 43,381 shares of the specialty chemicals company’s stock after buying an additional 3,948 shares during the period. Geode Capital Management LLC owned about 0.89% of Yield10 Bioscience worth $213,000 as of its most recent SEC filing. 17.79% of the stock is currently owned by institutional investors.

Yield10 Bioscience Company Profile (Get Rating)

Yield10 Bioscience, Inc, an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada. The company, through its Trait Factory, a trait gene discovery platform develops enhanced oilseed Camelina sativa for the production of proprietary seed products; and discovers high value genetic traits for the agriculture and food industries.

See Also